Comparing transdermal HRT therapies
when starting patients on HRT
|
Lenzetto® (spray) 
|
Gel
|
Patch
|
|---|---|---|
| Avoids first-pass liver metabolism | ||
| Yes1 | Yes1 | Yes1 |
| Dosing and administration | ||
| 1, 2 or 3 metered-dose sprays of Lenzetto® (each containing 1.53 mg of estradiol) applied to inner forearm daily2 |
Oestrogel® 750 μg
estradiol/actuation gel: Pump-pack
actuation. Two pumps (2.5g) of Oestrogel® once daily
(1.5 mg estradiol) is the usual starting dose3 Sandrena® 1 mg estradiol gel: Gel sachet. The usual starting dose is 1.0 mg estradiol (1.0 g gel) daily but the selection of the initial dose can be based on the severity of the patient’s symptoms. Dose can be readjusted after 2-3 cycles individually from 0.5 g to 1.5 g per day4 |
Evorel Sequi® 50 mcg estradiol/ day patch: adhesive patch delivering 25, 50, 75 and 100 mcg of estradiol over 24 hours5 |
| Drug half-life | ||
| Estradiol values did not return to baseline by 168 hours after the last dose7 |
Oestrogel® 750 μg estradiol/actuation
gel: 36 hours8 Sandrena® 1 mg estradiol gel: half-life not available9 |
Evorel Sequi® 50 mcg estradiol/day patch: 6.6 hours5 |
| Application site adverse events | ||
|
Skin irritation for Lenzetto®: uncommon (≥1/1,000 to
<1/100).2 Treatment-related application site reaction rate was similar to placebo10 |
Skin reactions for Oestrogel® and Sandrena®: range from common (≥1/100 to <1/10) to uncommon (≥1/1,000 to <1/100)3,4 | Evorel Sequi® local skin reactions (including pruritis and rash): common5 |
This table is intended for comparative information only and is based on information from approved Summary of Product Characteristics. Please refer to the individual Summary of Product Characteristics when making prescribing decisions.